高级搜索

含奥沙利铂方案与FOLFIRI方案一线化疗对K-ras基因不同状态晚期大肠癌患者的疗效及预后影响比较

徐可, 王少龙, 姜鹤群, 张杰

徐可, 王少龙, 姜鹤群, 张杰. 含奥沙利铂方案与FOLFIRI方案一线化疗对K-ras基因不同状态晚期大肠癌患者的疗效及预后影响比较[J]. 肿瘤防治研究, 2015, 42(03): 280-284. DOI: 10.3971/j.issn.1000-8578.2015.03.015
引用本文: 徐可, 王少龙, 姜鹤群, 张杰. 含奥沙利铂方案与FOLFIRI方案一线化疗对K-ras基因不同状态晚期大肠癌患者的疗效及预后影响比较[J]. 肿瘤防治研究, 2015, 42(03): 280-284. DOI: 10.3971/j.issn.1000-8578.2015.03.015
shu
XU Ke, WANG Shaolong, JIANG Hequn, ZHANG Jie. Comparison of Efficacy and Prognosis of Oxaliplatin-based Regimens and FOLFIRI Regimen as First-line Chemotherapy for Stage Ⅳ Colorectal Cancer Patients with Different K-ras Statuses[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 280-284. DOI: 10.3971/j.issn.1000-8578.2015.03.015
Citation: XU Ke, WANG Shaolong, JIANG Hequn, ZHANG Jie. Comparison of Efficacy and Prognosis of Oxaliplatin-based Regimens and FOLFIRI Regimen as First-line Chemotherapy for Stage Ⅳ Colorectal Cancer Patients with Different K-ras Statuses[J]. Cancer Research on Prevention and Treatment, 2015, 42(03): 280-284. DOI: 10.3971/j.issn.1000-8578.2015.03.015
shu

含奥沙利铂方案与FOLFIRI方案一线化疗对K-ras基因不同状态晚期大肠癌患者的疗效及预后影响比较

  • 610500 成都，成都医学院第一附属医院肿瘤科

详细信息
    作者简介:

    徐可（1986-），男，硕士，医师，主要从事消化道肿瘤的治疗研究

    通讯作者:

    王少龙，E-mail：wangslzlk@126.com

  • 中图分类号: R735.3+4

Comparison of Efficacy and Prognosis of Oxaliplatin-based Regimens and FOLFIRI Regimen as First-line Chemotherapy for Stage Ⅳ Colorectal Cancer Patients with Different K-ras Statuses

  • Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, China

HTML全文

    摘要
  • 摘要: 目的 探究含奥沙利铂方案与FOLFIRI方案对Ⅳ期结直肠癌化疗疗效及预后影响的差别与K-ras基因状态的关系。方法 收集2010年1月至2012年1月的118例接受含奥沙利铂方案或FOLFIRI方案化疗的Ⅳ期结直肠癌患者临床资料，统计患者的治疗有效率（ORR）、疾病控制率（DCR）、无进展生存时间（PFS）和总生存期（OS）。采用χ2检验比较各组临床因素差别和两种治疗方案的有效率及疾病控制率，采用Kaplan-Meier法比较无进展生存时间以及总生存期。结果 118例患者中，接受含奥沙利铂方案化疗的K-ras突变型患者PFS及OS较接受FOLFIRI方案化疗患者延长（P=0.048；P=0.037），ORR及DCR较接受FOLFIRI方案化疗患者无明显差别（P=0.961；P=0.931）。接受含奥沙利铂方案化疗的K-ras野生型患者ORR、DCR、PFS及OS较接受FOLFIRI方案化疗患者无明显差别（P=0.900；P=0.802；P=0.738；P=0.904）。结论 采用含奥沙利铂方案一线化疗较FOLFIRI方案对K-ras突变型Ⅳ期结直肠癌患者更有优势，而对于K-ras野生型Ⅳ期结直肠癌患者，含奥沙利铂方案与FOLFIRI方案疗效及预后情况相当。

     

    Abstract: Objective To compare the efficacy and prognosis of oxaliplatin-based regimens and FOLFIRI regimen as the first-line chemotherapy for stage Ⅳ colorectal cancer patients with different K-ras statuses. Methods We collected clinical data of 118 stage Ⅳ colorectal cancer patients treated with oxaliplatin-based regimens or FOLFIRI regimen as the first-line chemotherapy from Jan. 2010 to Jan. 2012. The cumulative survival rate, objective response rate(ORR), disease control rate(DCR), progression free survival(PFS) and overall survival(OS) of the cases were calculated. Chi-square test was used to compare the differences of clinical factors, ORR and DCR between different groups. Kaplan-Meier method was used to compare the differences of PFS and OS. Results Oxaliplatin-based regimens chemotherapy prolonged PFS and OS of the K-ras mutant patients compared with FOLFIRI regimen chemotherapy (P=0.048; P=0.037). ORR and DCR of the K-ras mutant patients treated with oxaliplatin-based regimens chemotherapy were not significantly different from those with FOLFIRI regimen chemotherapy (P=0.961; P=0.931). ORR, DCR, PFS and OS of the K-ras wide type patients treated with oxaliplatin-based regimens chemotherapy were not significantly different from those with FOLFIRI regimen chemotherapy (P=0.900; P=0.802; P=0.738; P=0.904). Conclusion Oxaliplatin-based regimens as the first-line chemotherapy is more beneficial than FOLFIRI regimen as the first-line chemotherapy for K-ras mutant stage Ⅳ colorectal cancer patients; however, the efficacy and prognosis of K-ras wild type stage Ⅳ colorectal cancer patients were not significantly different between oxaliplatin-based regimens and FOLFIRI regimen chemotherapy.

     

    • HTML全文
    • 参考文献(15)
  • [1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
    [2] Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan- European consensus on the treatment of patients with colorectal liver metastases[J]. Eur J Cancer, 2006, 42(14): 2212-21.
    [3] Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view[J]. Semin Liver Dis, 1984, 4(2): 170-9.
    [4] Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage Ⅳ colorectal cancer receiving combination chemotherapy without surgery as initial treatment[J]. J Clin Oncol, 2009, 27(20): 3379-84.
    [5] Van Culsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14): 1408-17.
    [6] Lin YL, Liang YH, Tsai JH, et al. Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients[J]. PLoS One, 2014, 9(2):e86789.
    [7] Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil,leuc ovorin,and oxliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J]. J Clin Oncol, 2009, 27 (5): 663-71.
    [8] Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with kras wild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol, 20 13, 31(16): 1931-8.
    [9] Brodowicz T, Ciuleanu TE, Radosavljevic D, et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase Ⅱ CECOG study[J]. Ann Oncol, 2013, 24(7): 1769-77.
    [10] Modest DP, Laubender RP, Stintzing S, et al. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first- line treatment with cetuximab combined with either CAPIRI or CAPOX: qn analysis of the German AIO KRK 0104 trial[J]. Acta Oncol, 2013, 52(5): 956-62.
    [11] Shen H, Yuan Y, Hu HG, et al. Clinical significance of K-ras and BRAF mulations in Chinese colorectal cancer patients[J]. World J Gastroenterol, 2011, 17(6): 809-16.
    [12] Mannan A, Hahn-Strömberg V. K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma[J]. APMIS, 2012, 120(6): 459-68.
    [13] Pasetto LM, Jirillo A, Iadicicco G, et al. FOLFOX versus FOLFIRI a comparison of regimens in the treatment of colorectal cancer metastases[J]. Anticancer Res, 2005, 25(1B): 563-76.
    [14] Sun Y, Guan ZZ, Jin ML, et al. A multicenter randomized phase Ⅱ trial of oxaliplatin in patients with advanced colorectal cancer[J]. Ai Zheng, 1999, 18(3): 237-40, 249. [孙燕, 管忠震, 金懋林, 等. 奥沙利铂单药或与氟尿嘧啶—甲酰四氢叶酸联合应用治疗晚 期大肠癌Ⅱ期临床试用报告[J]. 癌症, 1999, 18(3): 237-40, 249.]
    [15] Uemura N, Yamada Y. FOLFIRI regimen for metastatic or recurrent colorectal cancer[J].Gan To Kagaku Ryoh, 2006, 33(7): 90 4-6.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1299
  • HTML全文浏览量:  309
  • PDF下载量:  341
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-03-12
  • 修回日期:  2014-06-22
  • 刊出日期:  2015-03-24

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11648924 今日访问：16273

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭